Compare EIG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | COLL |
|---|---|---|
| Founded | 2000 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 1.2B |
| IPO Year | 2006 | 2015 |
| Metric | EIG | COLL |
|---|---|---|
| Price | $41.20 | $33.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.17 |
| AVG Volume (30 Days) | 201.5K | ★ 540.9K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.46 | ★ 1.73 |
| Revenue | ★ $858,700,000.00 | $780,567,000.00 |
| Revenue This Year | N/A | $5.93 |
| Revenue Next Year | $1.76 | N/A |
| P/E Ratio | $89.43 | ★ $19.11 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $35.73 | $23.23 |
| 52 Week High | $49.98 | $50.79 |
| Indicator | EIG | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 32.27 |
| Support Level | $40.58 | $31.01 |
| Resistance Level | $42.57 | $36.20 |
| Average True Range (ATR) | 0.79 | 1.24 |
| MACD | 0.31 | 0.12 |
| Stochastic Oscillator | 77.81 | 26.98 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.